Profile data is unavailable for this security.
About the company
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2007
- Employees--
- LocationAddex Therapeutics LtdChemin des Mines, 9PLAN-LES-OUATES 1202SwitzerlandCHE
- Phone+41 228841555
- Fax+41 228841556
- Websitehttps://www.addextherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organovo Holdings Inc | 1.58m | -11.95m | 13.16m | 14.00 | -- | 0.5262 | -- | 8.34 | -1.37 | -1.37 | 0.1811 | 2.87 | 0.0494 | -- | -- | 121,307.70 | -37.46 | -51.62 | -39.35 | -55.48 | -- | -- | -757.58 | -951.91 | -- | -- | 0.00 | -- | -- | -18.73 | 31.96 | -- | -21.29 | -- |
| Diffusion Pharmaceuticals Inc | 0.00 | -14.99m | 13.26m | 16.00 | -- | 0.5511 | -- | -- | -7.50 | -7.50 | 0.00 | 11.79 | 0.00 | -- | -- | 0.00 | -44.61 | -57.58 | -48.21 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -49.33 | -- | -- | -- |
| Graybug Vision Inc | 0.00 | -36.88m | 13.34m | 27.00 | -- | 0.3208 | -- | -- | -1.72 | -1.72 | 0.00 | 1.93 | 0.00 | -- | -- | 0.00 | -60.45 | -- | -64.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.17 | -- | -- | -- |
| Liminal BioSciences Inc | 296.82k | -22.77m | 13.35m | 48.00 | -- | 0.4429 | -- | 44.97 | -0.7349 | -0.2818 | 0.0096 | 0.9709 | 0.004 | -- | 0.2942 | 6,183.66 | -30.91 | -69.87 | -34.74 | -85.81 | -- | -- | -7,818.59 | -918.04 | -- | -- | 0.0373 | -- | -11.19 | -47.67 | 7.88 | -- | -50.47 | -- |
| Vyne Therapeutics Inc | 2.76m | -37.75m | 13.50m | 28.00 | -- | 0.3369 | -- | 4.89 | -0.675 | -0.4413 | 0.0492 | 0.6904 | 0.0431 | -- | 0.5235 | 98,678.57 | -58.89 | -109.14 | -75.22 | -133.50 | 50.27 | -- | -1,366.41 | -934.12 | -- | -- | 0.00 | -- | -29.71 | 85.38 | 71.31 | -- | -- | -- |
| Plus Therapeutics Inc | 73.00k | -18.77m | 13.53m | 14.00 | -- | 1.15 | -- | 185.36 | -0.8874 | -0.8874 | 0.0034 | 0.3501 | 0.0031 | -- | -- | 5,214.29 | -78.46 | -50.52 | -121.32 | -118.00 | -- | -- | -25,715.07 | -295.80 | -- | -25.66 | 0.3339 | -- | -100.00 | -- | -62.59 | -- | 16.54 | -- |
| Pulmatrix Inc | 4.82m | -21.85m | 13.61m | 24.00 | -- | 0.3884 | -- | 2.82 | -6.84 | -6.84 | 1.48 | 9.63 | 0.0943 | -- | 19.87 | 200,791.70 | -36.50 | -69.19 | -41.11 | -94.91 | -- | -- | -387.03 | -376.68 | -- | -- | 0.00 | -- | -59.09 | 43.99 | -21.03 | -- | -20.55 | -- |
| Ibio Inc | 2.17m | -48.92m | 13.84m | 105.00 | -- | 0.2868 | -- | 6.37 | -5.60 | -5.60 | 0.2482 | 5.37 | 0.019 | -- | 3.44 | 20,685.71 | -42.84 | -32.33 | -52.02 | -35.44 | 91.90 | -- | -2,251.43 | -1,396.73 | -- | -82.90 | 0.323 | -- | 0.5061 | 43.33 | -114.73 | -- | 48.82 | -- |
| Tricida Inc | 0.00 | -133.91m | 13.93m | 57.00 | -- | -- | -- | -- | -2.37 | -2.37 | 0.00 | -2.44 | 0.00 | -- | -- | 0.00 | -103.62 | -66.86 | -124.10 | -74.65 | -- | -- | -- | -- | -- | -12.43 | 3.30 | -- | -- | -- | 33.32 | -- | -16.85 | -- |
| Malachite Innovations Inc | 2.19m | -1.61m | 14.06m | 3.00 | -- | 5.39 | -- | 6.43 | -0.0286 | -0.0286 | 0.0356 | 0.0334 | 1.02 | -- | -- | -- | -75.18 | -- | -94.57 | -- | 19.33 | -- | -73.50 | -- | -- | -30.01 | 0.3091 | -- | -- | -- | -- | -- | -- | -- |
| Addex Therapeutics Ltd - ADR | -100.00bn | -100.00bn | 14.15m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0468 | -- | -- | -- | -- | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -18.42m | 14.26m | 16.00 | -- | 1.20 | -- | -- | -1.31 | -1.31 | 0.00 | 0.7656 | 0.00 | -- | -- | 0.00 | -107.04 | -- | -132.63 | -- | -- | -- | -- | -- | -- | -466.26 | 0.00 | -- | -100.00 | -- | -109.66 | -- | -56.66 | -- |
| Talis Biomedical Corp | 4.84m | -127.13m | 14.70m | 242.00 | -- | 0.0825 | -- | 3.04 | -4.64 | -4.64 | 0.1739 | 6.65 | 0.0161 | -- | 12.84 | 19,979.34 | -42.29 | -- | -49.40 | -- | -22.01 | -- | -2,629.45 | -- | 12.35 | -- | 0.00 | -- | -25.10 | -- | -110.73 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -58.20m | 14.83m | 56.00 | -- | 0.2484 | -- | -- | -2.77 | -2.77 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -57.68 | -- | -69.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -136.50 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -13.88m | 15.04m | 70.00 | -- | 0.5456 | -- | -- | -1.68 | -1.68 | 0.00 | 3.34 | 0.00 | -- | -- | -- | -37.36 | -70.63 | -42.29 | -83.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.42 | -- | -61.94 | -- |
Data as of Nov 30 2022. Currency figures normalised to Addex Therapeutics Ltd's reporting currency: US Dollar USD
3.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Sep 2022 | 320.00k | 2.94% |
| Renaissance Technologies LLCas of 30 Sep 2022 | 29.55k | 0.27% |
| FNY Capital Management LPas of 30 Sep 2022 | 22.50k | 0.21% |
| Millennium Management LLCas of 30 Sep 2022 | 19.96k | 0.18% |
| Citadel Securities LLCas of 30 Sep 2022 | 12.80k | 0.12% |
| Two Sigma Securities LLCas of 30 Sep 2022 | 12.08k | 0.11% |
| UBS Securities LLCas of 30 Sep 2022 | 7.03k | 0.07% |
| Tower Research Capital LLCas of 30 Sep 2022 | 124.00 | 0.00% |
| Old Mission Capital LLCas of 30 Sep 2022 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
